Table 1 Clinical research progress of immunotherapy for gastric cancer

PD-1

Nivolumab

Kang YK et al. [52]

ATTRACTION-4

Phase 3

first-line

nivolumab plus chemotherapy vs placebo plus chemotherapy

ORR: 57.5% vs 47.8%

Janjigian YY et al. [53]

CheckMate 649

Phase 3

first-line

nivolumab plus chemotherapy vs chemotherapy

ORR: 60% vs 45% in PD-L1 CPS > =5

Kang YK, Boku N et al. [54, 55]

ATTRACTION-2

Phase 3

third-line

nivolumab vs placebo

ORR: 32% vs 0%

Kelly RJ et al. [56]

CheckMate 577

Phase 3

adjuvant

nivolumab vs placebo

ORR not tested PFS: 22.4 vs 11.0 months

Fukuoka S et al. [57]

EPOC1603

Phase 1

second/third-line

nivolumab plus regorafenib

ORR: 44% in gastric cancer

Pembrolizumab

Shitara K et al. [58]

KEYNOTE-062

Phase 3

first-line

pembrolizumab vs pembrolizumab plus chemotherapy vs chemotherapy

ORR: 15% vs 49% vs 37%

Janjigian YY et al. [59]

KEYNOTE-811

Phase 3

first-line

pembrolizumab plus trastuzumab plus chemotherapy vs placebo plus trastuzumab plus chemotherapy

ORR: 74.4% vs 51.9%

Shitara K,Fuchs CS et al. [60, 61]

KEYNOTE-061

Phase 3

second-line

pembrolizumab vs paclitaxel

ORR: 17.3% vs 15.6% in PD-L1 CPS > =1

Chung HC et al. [62]

KEYNOTE-063

Phase 3

second-line

pembrolizumab vs paclitaxel

ORR: 13% vs 19%

Marabelle A et al. [63]

KEYNOTE-158

Phase 2

second/third-line

pembrolizumab

ORR: 34.3%

Kawazoe A et al. [64]

EPOC1706

Phase 2

first/second-line

pembrolizumab plus lenvatinib

ORR: 69%

Dostarlimab-gxly

https://clinicaltrials.gov/ct2/show/NCT02715284

GARNET

Phase 1

second-line

dostarlimab

Ongoing

Biomarker

Inhibitor

Study

Clinical trials

Phase

Therapeutic strategy

Group

Treatment effect

CTLA4

Ipilimumab

Shitara K et al. [65]

CheckMate 649

Phase 3

first-line

nivolumab plus ipilimumab vs chemotherapy

ORR: 70% vs 57% in MSI-H tumors

Janjigian YY et al. [66]

CheckMate 032

Phase 1/2

third-line

nivolumab 3 mg/kg vs nivolumab 1 mg/kg plus ipilimumab 3 mg/kg vs nivolumab 3 mg/kg plus ipilimumab 1 mg/kg

ORR: 12% vs 24% vs 8%

Bang YJ et al. [67]

NCT01585987

Phase 2

second-line

nivolumab vs best supportive care

ORR: 1.8% vs 7%

Tintelnot J et al. [68]

INTEGA

Phase 2

first-line

ipilimumab plus nivolumab plus trastuzumab vs chemotherapy plus nivolumab plus trastuzumab

Ongoing

Tremelimumab

Ralph C et al. [69]

researcher Christy Ralph

Phase 2

second-line

tremelimumab

ORR: 5%

Raimondi A et al. [70]

INFINITY

Phase 2

neoadjuvant

tremelimumab and durvalumab

Ongoing

Evrard C et al. [71]

DURIGAST

Phase 2

second-line

tremelimumab plus durvalumab plus chemotherapy vs durvalumab plus chemotherapy

LAG3

MbS-986,213

https://clinicaltrials.gov/ct2/show/NCT03662659

NCT03662659

Phase 2

first-line

MbS-986,213 plus chemotherapy

Ongoing

Relatlimab

https://clinicaltrials.gov/ct2/show/NCT03044613

NCT03044613

Phase 1

adjuvant

relatlimab plus nivolumab plus chemotherapy

Tebotelimab

https://clinicaltrials.gov/ct2/show/NCT04082364

NCT04082364

Phase 2/3

first-line

margetuximab plus tebotelimab plus chemotherapy

Tim3

INCAGN02390

https://clinicaltrials.gov/ct2/show/NCT03652077

NCT03652077

Phase 1

first-line

INCAGN02390

Ongoing

TIGIT

Tiragolumab

https://clinicaltrials.gov/ct2/show/NCT04933227

NCT04933227

Phase 2

first-line

tiragolumab plus atezolizumab plus chemotherapy

Ongoing

https://clinicaltrials.gov/ct2/show/NCT05251948

NCT05251948

Phase 2

second-line

tiragolumab plus atezolizumab plus chemotherapy

Recruiting

OX40

INBRX-106

https://clinicaltrials.gov/ct2/show/NCT04198766

NCT04198766

Phase 1

second/third-line

INBRX-106 with or without pembrolizumab

Recruiting